As a specialized US-based synthesis laboratory, PX1 Research provides research-grade Bronchogen formulated for automated high-throughput screening and in vitro assay platforms. Every batch undergoes rigorous RP-HPLC and ESI-MS analytical testing to guarantee precise peptide sequence identity and lot-to-lot consistency. Our ISO 17025 accredited quality verification ensures high-throughput research facilities receive ultra-pure compounds free from endotoxins and synthesis impurities.
As a specialized US-based synthesis laboratory, PX1 Research provides research-grade Bronchogen formulated for automated high-throughput screening and in vitro assay platforms. Every batch undergoes rigorous RP-HPLC and ESI-MS analytical testing to guarantee precise peptide sequence identity and lot-to-lot consistency. Our ISO 17025 accredited quality verification ensures high-throughput research facilities receive ultra-pure compounds free from endotoxins and synthesis impurities.
A professional manufacturer for Bronchogen high-throughput screening provides ultra-pure, HPLC/MS-verified short-chain peptide reagents optimized for automated assay platforms, target identification, and cellular expression research. PX1 Research delivers USA-manufactured, ISO 17025-tested Bronchogen with lot-specific COAs, certified purity exceeding 98%, and low endotoxin thresholds specifically validated for demanding in vitro screening workflows.
High-throughput screening (HTS) protocols require exceptional chemical purity and batch reproducibility to ensure automated dispensers, microplate readers, and robotic assay systems yield actionable data. Impurities such as truncation sequences, TFA salts, or bacterial endotoxins introduce noise into cellular viability screens and receptor binding assays. By manufacturing Bronchogen under strict ISO 17025 and GMP-compliant operational standards, PX1 Research provides high-throughput laboratories with reliable target compounds engineered to eliminate baseline variance across large-scale experimental runs.
Bronchogen is a synthetic regulatory peptide studied extensively within the field of peptide-mediated gene regulation and cell signaling. Composed of a targeted amino acid sequence (Ala-Glu-Asp-Pro), this short-chain peptide exhibits distinct physicochemical properties that dictate its handling and stability within automated liquid handling systems.
Because of its small molecular weight and ionic profile, Bronchogen displays rapid solubility in standard aqueous assay buffers such as phosphate-buffered saline (PBS) and Tris-HCl. Researchers investigating short-chain peptide bioregulators utilize Bronchogen due to its predictable structural stability under physiological pH conditions. Accurate structural characterization via mass spectrometry ensures that every aliquot synthesized by PX1 Research contains the exact molecular mass required for precision quantitative assays.
Preclinical evaluations of Bronchogen primarily focus on respiratory epithelial cell lines, chromatin structure modification, and inflammatory signaling pathways. In vitro assays demonstrate that Bronchogen interacts with specific nuclear histone proteins and promoter regions, potentially modulating transcriptomic profiles associated with cellular differentiation and tissue maintenance.
In cell culture models utilizing human bronchial epithelial cells (e.g., 16HBE14o- or BEAS-2B), exposure to Bronchogen has been observed to alter the expression of surfactant proteins and tight junction markers. Further data from rodent models suggest that short peptide sequences can penetrate cellular membranes to interact directly with nuclear DNA sequence motifs. Researchers seeking broader context on genomic interactions can explore peer-reviewed findings indexed in the PX1 research library hub.
High-throughput screening platforms rely on miniaturized, parallelized assays—such as 96-well, 384-well, or 1536-well microplate formats—to evaluate peptide binding kinetics, enzymatic modulation, and cytotoxicity. Bronchogen’s high solubility and chemical stability render it ideal for automated liquid handling workstations requiring automated serial dilutions and reagent dispensing.
To ensure high assay fidelity during multi-hour assay runs, researchers must maintain consistent peptide concentration without precipitation or surface adsorption. PX1 Research synthesizes Bronchogen with low hydrophobic variability, minimizing nonspecific adherence to polypropylene or polystyrene assay plates. This property guarantees consistent effective concentrations across all wells, protecting screening projects against false-positive or false-negative readouts.
When conducting screening experiments, baseline noise caused by residual solvent, residual trifluoroacetic acid (TFA), or bacterial lipopolysaccharide (LPS) can invalidate entire screening libraries. PX1 Researchsubjects every single batch of Bronchogen to exhaustive analytical validation before release to academic and commercial facilities.
Purity is verified via reverse-phase high-performance liquid chromatography (RP-HPLC), ensuring that target purity routinely exceeds 98.0%. Electrospray ionization mass spectrometry (ESI-MS) confirms exact molecular weight and structural integrity. Furthermore, we apply strict endotoxin testing standards using chromogenic LAL assays to ensure endotoxin levels remain below 0.01 EU/mg, preventing unspecific immune signaling responses in cell-based assays.
In high-throughput comparative profiling, researchers frequently screen Bronchogen alongside other short regulatory peptides to map differential gene activation patterns. For instance, while Bronchogen selectively target respiratory cell transcriptomics, the synthetic dipeptide Vilon is screened primarily for immunomodulatory and chromatin unwinding activity across splenocyte and lymphocyte cultures. Similarly, the tripeptide Cartalax is prioritized in cartilage and connective tissue repair assays, and Epitalon is evaluated for telomerase activation and neuroendocrine signaling pathways.
Screening these related molecules simultaneously allows high-throughput research teams to identify tissue-specific response markers, receptor cross-reactivity, and structure-activity relationships (SAR). Using uniform, ultra-pure compounds manufactured under the exact same synthesis parameters ensures that observed activity differences stem entirely from primary sequence variations rather than lot purity discrepancies.
Proper reconstitution and storage procedures are essential to preserving peptide integrity across high-throughput screening campaigns. Bronchogen is supplied as a lyophilized white powder under argon packaging to prevent oxidation and atmospheric moisture absorption.
For optimal stability, reconstitute the lyophilized powder using sterile, deionized water or sterile PBS (pH 7.4). Avoid high-shear vortexing; gentle inversion or mild agitation is recommended to bring the peptide into complete solution. Reconstituted stock solutions should be aliquoted into single-use polypropylene cryovials to prevent freeze-thaw degradation. Stock solutions stored at -80°C maintain chemical stability over extended experimental timelines. Specific handling details for this research compound are documented on the official Bronchogen product page.
PX1 Research operates dedicated peptide synthesis facilities located in California and Arizona. By retaining 100% of our manufacturing footprint within the USA, we maintain strict oversight over raw material sourcing, solid-phase peptide synthesis (SPPS), purification, and analytical verification.
For institutional laboratories requiring continuous bulk quantities for screening libraries, PX1 Research provides customizable lot sizes, standard operating protocol alignment, and rapid fulfillment. Qualified academic and industrial investigators can establish wholesale laboratory accounts to access dedicated account management and scheduled delivery arrangements. View our full comprehensive catalog of research peptides to coordinate compound libraries for upcoming screening initiatives.
What is Bronchogen, and what is its primary use in laboratory research?
Bronchogen is a synthetic short-chain regulatory peptide (Ala-Glu-Asp-Pro) supplied strictly as a research compound for in vitro assays, gene expression profiling, and preclinical screening models. It is not for human or veterinary use.
Why is PX1 Research considered a preferred manufacturer for Bronchogen high-throughput screening?
PX1 Research provides USA-manufactured peptides verified by ISO 17025 accredited third-party laboratories using RP-HPLC and ESI-MS. Every lot includes a detailed Certificate of Analysis (COA) detailing purity, mass verification, and endotoxin levels (<0.01 EU/mg).
What purity level is required for Bronchogen in automated screening assays?
High-throughput screening typically requires a purity threshold of ≥98.0%. Lower purity levels introduce synthesis byproducts and truncation sequences that interfere with spectrophotometric readings, cell viability assays, and target binding kinetics.
How is endotoxin testing performed on Bronchogen lots?
PX1 Research utilizes kinetic chromogenic Limulus Amebocyte Lysate (LAL) assays to quantify endotoxin concentrations per lot. Endotoxin control is critical to prevent non-specific inflammatory responses in cellular screening platforms.
What solvent is recommended for reconstituting Bronchogen for cell culture screening?
Bronchogen readily dissolves in sterile endotoxin-free water or sterile phosphate-buffered saline (PBS, pH 7.4). For long-term automated liquid handler reservoir stability, avoid DMSO unless required by specific assay protocols.
Can Bronchogen be supplied in bulk or customized plate formats for screening?
Yes. Institutional facilities can establish wholesale accounts to request customized vial sizes, microplate pre-weighed aliquots, or specific lot reservations to support large-scale high-throughput screening projects.
What is the recommended long-term storage condition for lyophilized Bronchogen?
Lyophilized Bronchogen should be stored at -20°C or -80°C in a dry environment protected from light. Under these conditions, the un-reconstituted peptide remains stable for up to 24 months.
Does PX1 Research provide lot-specific analytical documentation?
Yes. Every shipment of Bronchogen includes a lot-specific Certificate of Analysis featuring full RP-HPLC chromatograms, mass spectrometry reports, and endotoxin test results.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.